A Kyoto University spinout company having production technologies to generate high performance artificial blood cells from stem cells. Their Mylc cell series are highly controlled immature dendritic cells suitable for evaluation of efficacy of drug discovery and safety assessment. Recently launched cMylc kit is exclusively designed for COVID-19 vaccines and drug development. The coronavirus optimised optimized myeloid lineage cells works as host cells with giving stable and robust performances for your research on COVID-19.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 1-36 Goryouoohara,nishikyo-Ku, Kyoto,kyoto 615-8245,japan
- in****@****ies.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- micantechnologies.com
- HQ
- Kyoto, Kyoto
Mican Technologies Questions
Mican Technologies's website is micantechnologies.com
Mican Technologies's LinkedIn profile is https://jp.linkedin.com/company/mican-technologies-ltd
Mican Technologies has
9 employees.
View email and phone details for 9
employees at Mican Technologies.
Mican Technologies's industry is
Biotechnology Research
Mican Technologies's top competitors are
Algal Bio,
Run.edge,
Luca Science Inc.,
Yukai Engineering Inc,
Cyfuse Biomedical K.k.,
Mican,
Mican Technologies Inc.,
Biophenolics Inc.,
Purec,
Biolabs Heidelberg.
Mican Technologies's support email address is info@micantechnologies.com
Mican Technologies's categories are Biotechnology Research
Mican Technologies's founding year is 2016
